Aspirin-exacerbated asthma

Allergy, Asthma and Clinical Immunology

Volumn 4, Issue 2, 2008, Pages 75-83

  Varghese, Mathew ^a   Lockey, Richard F ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Aspirin desensitization; Aspirin exacerbated asthma; Aspirin exacerbated respiratory disease; Aspirin sensitive asthma; Cysteinyl leukotriene; Leukotriene; Leukotriene C4; Leukotriene C4 synthase

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 1; GLUCOCORTICOID; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; MONTELUKAST; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; ZAFIRLUKAST; ZILEUTON;

ARTICLE; ASTHMA; CLINICAL FEATURE; DESENSITIZATION; DISEASE EXACERBATION; HUMAN; NOSE CONGESTION; NOSE POLYP; PATHOGENESIS; PREVALENCE; RHINORRHEA;

EID: 45849135664     PISSN: 17101484     EISSN: None     Source Type: Journal    
DOI: 10.2310/7480.2008.00007     Document Type: Article

References (92)

1. Widal MF, Abrami P, Lemoyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922;30:189-92.
2. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-21.
3. Vanselow N. Bronchial asthma induced by indomethacin. Ann Intern Med 1967;66:568-72.
4. Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology 1996;103:890-2.
5. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. Allergy Clin Immunol 2006;118: 773-86.
6. Szczeklik A, Niankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 2000;55 Suppl 2:S42-4.
7. Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax 2000;55 Suppl 2:S45-7.
8. Mastalerz L, Setkowicz M, Sczceklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep 2005;5: 277-83.
9. Kim SH, Ye YM, Lee SK, Park HS. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol 2006;6:266-70.
10. Chiej R. Encyclopaedia of medicinal plants. MacDonald; 1984.
11. Rainsford KD. Aspirin and the salicylates. London: Butterworths; 1984.
12. Vane JR, Botting RM. Aspirin and other salicylates. London: Chapman and Hall Medical Publishers; 1992.
13. Verg E, Plumpe G, Schultheis H. Meilensteine: the official Bayer publication in commemoration of the centenary of aspirin's release. 1989.
14. McTavish J. What's in a name? Aspirin and the American Medical Association. Bull Hist Med 1987;61:364-5.
15. Buselmeier TJ. Combination urea and salicyclic acid ointment nail avulsion in nondystrophic nails. Cutis 1980;25:397, 405.
16. Pullman H, Lennartz KJ, Steigleder GK. Effect of salicylic acid on epidermal cell proliferation kinetics in psoriasis. Arch Dermatol Forsch 1975;251:271-5.
17. Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Clinical guidelines for the medical management of left sided ulcerative colitis and ulcerative proctitis. Inflamm Bowel Dis 2006;12:972-8.
18. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006;295:306-13.
19. Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006;38:415-28.
20. Aaron TH, Muttitt EL. Reactions to acetylsalicylic acid. Can Med Assoc J 1982;126:609-11.
21. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68: 975-83.
22. Kalyoncu AF. Aspirin-induced asthma needs a classification. Allergol Immunopathol (Madr) 2000;28:334-5.
23. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-21.
24. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
25. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002;57:569-74.
26. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22.
27. Kasper L, Sladek K, Duplaga M, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003;58:1064-6.
28. Kalyoncu AF, Karakaya G, Sahin AA, et al. Occurrence of allergic conditions in asthmatics with analgesic intolerance. Allergy 1999; 54:428-35.
29. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. ALANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432-6.
30. Lockey RF. Aspirin-improved ASA triad. Hosp Pract 1978;13(8): 129, 131, 133.
31. Pierzchalska M, Mastalerz L, Sanak M, et al. A moderate and unspecific release of cysteinyl-leukotrienes by aspirin from peripheral blood leukocytes precludes its value for aspirin-sensitivity testing in asthma. Clin Exp Allergy 2000;30:1785-91.
32. Gray PA, Warner TD, Vojnovic I, et al. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol 2002;137:1031-8.
33. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67-9.
34. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-93.
35. Szczeklik A, Sanak M. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 2002;32:339-42.
36. Vane SJ. Aspirin and other anti-inflammatory drugs. Thorax 2000; 55 Suppl 2:S3-9.
37. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8.
38. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
39. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971;231:235-7.
40. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997;26:2-10.
41. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
42. Nasser SM, Poster R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90-6.
43. Nasser S, Christie PE, Pfister R, et al. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996; 51:64-70.
44. Sousa AR, Lams BE, Pfister R, et al. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997;156:1384-9.
45. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-46.
46. Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin induced asthma. Am J Respir Crit Care Med 2002;166:301-6.
47. Chandrasekharan NV, Hu Dai, Lamar Turepu Roos K, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31.
48. Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is down-expressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Cell Mol Biol 2000;160:291-6.
49. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391-8.
50. Mullol J, Fernandez-Morata JC, Roca-Ferrer J, et al. Cyclooxygenase 1 and cyclooxygenase 2 expression in abnormally regulated in human nasal polyps. J Allergy Clin Immunol 2002;109: 824-30.
51. Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. Lancet 1995;345:1056.
52. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995;345:436-8.
53. Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 2006;209:392-9.
54. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97:105-9.
55. Sanak M, Kielbasa B, Bochenek G, Szczeklik A. Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy 2004;34(12):1899-904.
56. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;153: 572-5.
57. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996;153:567-71.
58. Lockey RF, Rucknagel DL, Vanselow NA. Familial occurrence of asthma, nasal polyps and aspirin intolerance. Ann Intern Med 1973;78:57-63.
59. Miller FF. Aspirin-induced bronchial asthma in sisters. Ann Allergy 1971;29:263-5.
60. Von Maur K, Adkinson NF Jr, Van Metre TE Jr, et al. Aspirin intolerance in a family. J Allergy Clin Immunol 1974;54:380-95.
61. Szczeklik A, Sanak M. Genetic mechanisms in aspirin-induced asthma. Am J Respir Crit Care Med 2000;161 (2 Pt 2):S142-6.
62. Kennedy BP, Diehl RE, Boie Y, et al. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). J Biol Chem 1991;266:8511-6.
63. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A 1994;91:7663-7.
64. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000;23(3):290-6.
65. Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002;109:936-42.
66. Nizankowska E, Duplaga M, Bochenek G, Szczeklik A, on behalf of the AIANE Project. Clinical course of aspirin-induced asthma: results of AIANE. In: Szczeklik A, Gryglewski R, Vane J, editors. Eicosanoids, aspirin and asthma. New York: Marcel Dekker; 1998. p. 451-71.
67. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:474-8.
68. Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31:219-25.
69. Yoshida S, Ishizaki Y, Onuma K, et al. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000;106:1201-2.
70. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis Rheum 2002; 46:2201-6.
71. Baldassarre S, Schandene L, Choufani G, Michils A. Asthma attacks induced by low doses of celecoxib, aspirin and acetaminophen. J Allergy Clin Immunol 2006;117:215-7.
72. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976;57:440-8.
73. Pleskow WW, Stevenson DD, Mathison DA, et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982;69(1 Pt 1):11-9.
74. Sclano G. Refractory period to aspirin after aspirin-induced asthma. J Allergy Clin Immunol 1982;70:220-1.
75. Micheletto C, Tognella S, Visconti M, et al. Changes in urinary LTE(4) and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics. Respir Med 2006; 100(12):2144-50. Epub 2006.
76. White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97:190-5.
77. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal antiinflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977;60:276-84.
78. Setipane RA, Stevenson DD. Cross-sensitivity with acetaminophen in aspirin sensitive subjects with asthma. J Allergy Clin Immunol 1989;84:26-33.
79. Dahlen S-E, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
80. Yoshida S, Sakamoto H, Ishizaki Y, et al. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000;30:64-70.
81. Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949-95.
82. Fuji, et al. Effect of endoscopic sinus surgery on aspirin-induced asthma. Jpn J Rhinol 2004;43(2):175-81.
83. McFadden EA, Woodson BT, Fink JN, Toohill RJ. Surgical treatment of aspirin triad sinusitis. Am J Rhinol 1997;11:263-70.
84. Hosemann W. Surgical treatment of nasal polyposis in patients with aspirin intolerance. Thorax 2000;55(Suppl 2):S87-90.
85. Amar YG, Frenkiel S, Sobol SE. Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad. J Otolaryngol 2000;29:7-12.
86. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980;66:82-8.
87. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180-6.
88. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347(19):1493-9.
89. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002;32:1491-6.
90. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005;95:330-5.
91. Wong JT, Nagy CS, Krinzman SJ, et al. Rapid oral challenge- desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 2000;105:997-1001.
92. Stevenson DD, Mehra PK, White AA, et al. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2005;116:755-60.